Advertisement

Serum monomeric α2-macroglobulin as a clinical biomarker in diabetes

      Abstract

      Objective

      Despite the number of potential biomarker proteins for diabetes, very few of them have proven useful as clinically beneficial indicators, because of the technical difficulties associated with their identification among highly abundant serum proteins. We attempted to identify a protein with distinguishable expression in human diabetes.

      Methods

      We applied a highly efficient strategy for the purification of endogenous low abundance proteins from diabetic and non-diabetic serum samples. Extracted sera were fractionated by SDS-PAGE and protein bands were isolated and analyzed by mass spectrometry using an ion-trap mass spectrometer. The identities of the proteins were confirmed by western blotting and the serum levels evaluated.

      Results

      A significantly upregulated protein in diabetic patients was identified as monomeric α2-macroglobulin. Its tetramer, another dominant circulating molecular form, was only marginally increased in diabetes.

      Conclusion

      Serum monomeric α2-macroglobulin is highly expressed in many diabetic subjects. It is identical to the human ‘cardiac isoform of α2-macroglobulin’ described in the literature, a well-known acute phase serum biomarker protein mechanistically involved in cardiac and atherosclerotic diseases.

      Highlights

      • Proteome analysis revealed distinct expression of monomeric α-2 macroglobulin in human diabetic subjects.
      • It is identical to the human ‘cardiac isoform of α-2 macroglobulin’.
      • ‘Cardiac isoform of α-2 macroglobulin’ is a well-described biomarker protein.
      • Serum monomeric α-2 macroglobulin could serve as a clinical biomarker.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Harpel P.C.
        Studies on human plasma alpha 2-macroglobulin-enzyme interactions. Evidence for proteolytic modification of the subunit chain structure.
        J Exp Med. 1973; 138: 508-521
        • James K.
        • Merriman J.
        • Gray R.S.
        • Duncan L.J.
        • Herd R.
        Serum alpha 2-macroglobulin levels in diabetes.
        J Clin Pathol. 1980; 33: 163-166
        • Lisowska-Myjak B.
        • Pachecka J.
        • Kaczynska B.
        • Miszkurka G.
        • Kadziela K.
        Serum protease inhibitor concentrations and total antitrypsin activity in diabetic and non-diabetic children during adolescence.
        Acta Diabetol. 2006; 43: 88-92
        • Ahmad J.
        • Singh M.
        • Saleemuddin M.
        A study of plasma alpha-2-macroglobulin levels in type 2 diabetic subjects with microalbuminuria.
        J Assoc Physicians India. 2001; 49: 1062-1065
        • McMillan D.E.
        Alpha2-macroglobulin in diabetes.
        Lancet. 1976; 2: 1020-1021
        • de Sain-van der Velden M.G.
        • Rabelink T.J.
        • Reijngoud D.J.
        • et al.
        Plasma alpha 2 macroglobulin is increased in nephrotic patients as a result of increased synthesis alone.
        Kidney Int. 1998; 54: 530-535
        • Ceriello A.
        • Giugliano D.
        • Quatraro A.
        • Stante A.
        • Dello Russo P.
        • Torella R.
        Increased alpha 2-macroglobulin in diabetes: a hyperglycemia related phenomenon associated with reduced antithrombin III activity.
        Acta Diabetol Lat. 1989; 26: 147-154
        • Gray R.S.
        • James K.
        • Merriman J.
        • et al.
        Alpha 2-macroglobulin and proliferative retinopathy in type 1 diabetes.
        Horm Metab Res. 1982; 14: 389-392
        • Watzke H.
        • Schernthaner G.
        • Schnack C.
        • Schwarz H.P.
        • Prskavec F.
        • Freyler H.
        Coagulation factors of contact phase of haemostasis are normal in well-controlled type-I diabetic patients despite presence of diabetic retinopathy.
        Diabetes Res. 1988; 7: 197-200
        • Annapoorani P.
        • Dhandapany P.S.
        • Sadayappan S.
        • Ramasamy S.
        • Rathinavel A.
        • Selvam G.S.
        Cardiac isoform of alpha-2 macroglobulin–a new biomarker for myocardial infarcted diabetic patients.
        Atherosclerosis. 2006; 186: 173-176
        • Mariappan M.
        • Selvamurugan N.
        • Rajamanickam C.
        Purification and characterization of a high-molecular-weight protein induced in rat serum during the development of cardiac hypertrophy.
        Arch Biochem Biophys. 1990; 281: 287-297
        • Prabhakar R.
        • Rajamanickam C.
        Serum protein of 135-kDa molecular weight–a molecular signal for cardiac hypertrophy.
        Arch Biochem Biophys. 1993; 302: 425-430
        • Rajamanickam C.
        • Sakthivel S.
        • Babu G.J.
        • Lottspeich F.
        • Kadenbach B.
        Cardiac isoform of alpha-2 macroglobin, a novel serum protein, may induce cardiac hypertrophy in rats.
        Basic Res Cardiol. 2001; 96: 23-33
        • Rajamanickam C.
        • Sakthivel S.
        • Kurian Joseph P.
        • Athimoolam Janarthanan R.
        A novel serum protein of molecular weight 182 kDa: a molecular marker for an early detection of increased left ventricular mass in patients with cardiac hypertrophy.
        J Cardiovasc Risk. 1998; 5: 335-338
        • Rajan S.
        • Radhakrishnan J.
        • Rajamanickam C.
        Direct injection and expression in vivo of full-length cDNA of the cardiac isoform of alpha-2 macroglobulin induces cardiac hypertrophy in the rat heart.
        Basic Res Cardiol. 2003; 98: 39-49
        • Moore R.E.
        • Young M.K.
        • Lee T.D.
        Qscore: an algorithm for evaluating SEQUEST database search results.
        J Am Soc Mass Spectrom. 2002; 13: 378-386
        • Washburn M.P.
        • Wolters D.
        • Yates 3rd, J.R.
        Large-scale analysis of the yeast proteome by multidimensional protein identification technology.
        Nat Biotechnol. 2001; 19: 242-247
        • Bjorhall K.
        • Miliotis T.
        • Davidsson P.
        Comparison of different depletion strategies for improved resolution in proteomic analysis of human serum samples.
        Proteomics. 2005; 5: 307-317
        • Millioni R.
        • Tolin S.
        • Puricelli L.
        • et al.
        High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity.
        PLoS One. 2011; 6: e19603
        • Kawashima Y.
        • Fukutomi T.
        • Tomonaga T.
        • et al.
        High-yield peptide-extraction method for the discovery of subnanomolar biomarkers from small serum samples.
        J Proteome Res. 2010; 9: 1694-1705
        • Eng J.K.
        • Fischer B.
        • Grossmann J.
        • Maccoss M.J.
        A fast SEQUEST cross correlation algorithm.
        J Proteome Res. 2008; 7: 4598-4602
        • White R.
        • Janoff A.
        • Godfrey H.P.
        Secretion of alpha-2-macroglobulin by human alveolar macrophages.
        Lung. 1980; 158: 9-14
        • Milosavljevic T.S.
        • Petrovic M.V.
        • Cvetkovic I.D.
        • Grigorov II,
        DNA binding activity of C/EBPbeta and C/EBPdelta for the rat alpha2-macroglobulin gene promoter is regulated in an acute-phase dependent manner.
        Biochemistry (Mosc). 2002; 67: 918-926
        • Armstrong P.B.
        Role of α2-macroglobulin in the immune responses of invertebrates.
        Invert Surviv J. 2010; 7: 165-180
        • Rathinavel A.
        • Dhandapany P.S.
        • Annapoorani P.
        • Ramasamy S.
        • Selvam G.S.
        Cardiac isoform of alpha-2 macroglobulin as a novel diagnostic marker for cardiac diseases.
        Eur J Cardiovasc Prev Rehabil. 2005; 12: 601-603
        • Subbiah R.
        • Chengat V.
        • Clifton J.D.
        • et al.
        Cardiac isoform of alpha 2 macroglobulin and its reliability as a cardiac marker in HIV patients.
        Heart Lung Circ. 2010; 19: 93-95
        • Padmasekar M.
        • Nandigama R.
        • Wartenberg M.
        • Schluter K.D.
        • Sauer H.
        The acute phase protein alpha2-macroglobulin induces rat ventricular cardiomyocyte hypertrophy via ERK1,2 and PI3-kinase/Akt pathways.
        Cardiovasc Res. 2007; 75: 118-128
        • Watanabe T.
        • Sato K.
        • Itoh F.
        • Wakabayashi K.
        • Shichiri M.
        • Hirano T.
        Endogenous bioactive peptides as potential biomarkers for atherosclerotic coronary heart disease.
        Sensors (Basel). 2012; 12: 4974-4985
        • Watanabe T.
        • Nishio K.
        • Kanome T.
        • et al.
        Impact of salusin-α and -β on human macrophage foam cell formation and coronary atherosclerosis.
        Circulation. 2008; 117: 638-648
        • Watanabe T.
        • Suguro T.
        • Sato K.
        • et al.
        Serum salusin-α levels are decreased and correlated negatively with carotid atherosclerosis in essential hypertensive patients.
        Hypertens Res. 2008; 31: 463-468